The available limited data from recent studies and real‐world data suggest potential complementary and additive effects and in our opinion combination treatment GLP‐1 RA and SGLT‐2 inhibitors should also be considered early in the management people with T2D and CKD to address residual cardio‐renal risk (Tiers 1 or 2).10, 25, 45. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.